| Literature DB >> 27301510 |
Akihiro Ueno1, Nagaaki Katoh, Osamu Aramaki, Masatoshi Makuuchi, Shu-Ichi Ikeda.
Abstract
Systemic light chain (AL) amyloidosis is caused by abnormal plasma cell clones producing amyloidogenic light chains. The standard treatment is therefore chemotherapy targeting these clones, however, some patients are ineligible due to liver dysfunction. For these patients, preceding liver transplantation (LT) and following chemotherapy is a possible treatment option. We herein report a 58-year-old man with advanced hepatic AL amyloidosis who was successfully treated using this strategy. Previously reported cases treated with LT for this condition were reviewed, however, the outcomes were not favorable. We additionally investigated potential prognostic factors of this treatment approach to improve the outcome of these patients.Entities:
Mesh:
Substances:
Year: 2016 PMID: 27301510 DOI: 10.2169/internalmedicine.55.6675
Source DB: PubMed Journal: Intern Med ISSN: 0918-2918 Impact factor: 1.271